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Background: There is accumulating evidence for an increased cardiovascular burden in inflammatory arthritis, but
the true magnitude of this cardiovascular burden is still debated. We sought to determine the prevalence rate of
non-fatal cardiovascular disease (CVD) in inflammatory arthritis, diabetes mellitus and osteoarthritis (non-systemic
inflammatory comparator) compared to controls, in primary care.
Methods: Data on CVD morbidity (ICPC codes K75 (myocardial infarction), K89 (transient ischemic attack), and/or
K90 (stroke/cerebrovascular accident)) from patients with inflammatory arthritis (n = 1,518), diabetes mellitus
(n = 11,959), osteoarthritis (n = 4,040) and controls (n = 158,439) were used from the Netherlands Information
Network of General Practice (LINH), a large nationally representative primary care based cohort. Data were analyzed
using multi-level logistic regression analyses and corrected for age, gender, hypercholesterolemia and hypertension.
Results: CVD prevalence rates were significantly higher in inflammatory arthritis, diabetes mellitus and osteoarthritis
compared with controls. These results attenuated - especially in diabetes mellitus - but remained statistically
significant after adjustment for age, gender, hypertension and hypercholesterolemia for inflammatory arthritis
(OR = 1.5 (1.2-1.9)) and diabetes mellitus (OR = 1.3 (1.2-1.4)). The association between osteoarthritis and CVD reversed
after adjustment (OR = 0.8 (0.7-1.0)).
Conclusions: These results confirm an increased prevalence rate of CVD in inflammatory arthritis to levels
resembling diabetes mellitus. By contrast, lack of excess CVD in osteoarthritis further suggests that the systemic
inflammatory load is critical to the CVD burden in inflammatory arthritis.Background
In inflammatory arthritis patients the cardiovascular
disease (CVD) burden is more prevalent, best exemplified
by higher rates of cardiovascular mortality and morbidity
in rheumatoid arthritis (RA) patients [1-3]. The increased
CVD risk in inflammatory arthritis patients can not be
fully explained by classical risk factors [4,5]. Additionally,
chronic inflammation either directly or indirectly via insu-
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reproduction in any medium, provided the orhas emerged as potential mechanism for the excessive
CVD risk in inflammatory arthritis patients [6].
The true magnitude of the cardiovascular burden in
inflammatory arthritis is still debated, since outcomes of
studies assessing CVD prevalence and incidence are dif-
ficult to compare due to differences in study design and
study populations. Most studies are performed in
secondary care-based cohorts and only a minority in
community-based settings, which, as a consequence,
may lead to an overestimation of the CVD burden due
to an overrepresentation of inflammatory arthritis
patients with more severe disease [1,7,8]. This problem
can be solved by using data from electronic medicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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flammatory arthritis patients in primary care have a
broader spectrum of disease severity, which may result
in a more accurate estimate of the CVD prevalence. In
the Netherlands, GPs have a gatekeeper role for access
to specialized care. All Dutch inhabitants are listed with
a general practice, and the GP is the first professional to
be consulted for health problems.
Using data from GPs also makes it possible to com-
pare morbidity and health care utilization of inflamma-
tory arthritis patients with other patient groups or
healthy individuals. This latter possibility is interesting,
because we recently observed that the magnitude of
CVD risk in rheumatoid arthritis patients approached
that of diabetes mellitus [9,10], a well-established cardio-
vascular risk factor. In these studies RA patients in spe-
cialized care were compared with diabetes mellitus
patients from a population-based cohort. Using data
from patients in primary care may result in a better esti-
mation of the CVD risk of inflammatory arthritis and
diabetes mellitus patients, because these patient popula-
tions are representative for the total patient population.
Additionally, it would not only be interesting to com-
pare CVD risk between inflammatory arthritis and dia-
betes mellitus patients, but also to include a group of
osteoarthritis patients and controls. Using controls
makes it possible to compare the CVD risk in the pa-
tient groups with ´healthy individuals. If indeed inflam-
mation enhances CVD risk, one may hypothesize that
osteoarthritis of the knee and/or hip (a non-systemic ‘in-
flammatory’ arthritis) will be associated with a less pro-
nounced CVD burden. Against this background, we
determined the non-fatal CVD prevalence rate in
patients with inflammatory arthritis, diabetes mellitus,
and osteoarthritis, as compared to patients without these
disorders, in primary care.
Methods
Study population
Data were used from the Netherlands Information Net-
work of General Practice (LINH). These data were
retrieved from EMRs kept by a nationally representative
sample of approximately 160 GPs working in 96 general
practices with 360,000 registered patients in 2006. Data
include information on consultations, morbidity, pre-
scriptions and referrals to other healthcare professionals.
Practices as well as patients are representative for the
Dutch population [11,12].
Diagnoses were recorded using the International Clas-
sification of Primary Care (ICPC-1) coding system [13].
When issuing a prescription, a diagnostic code was
recorded, and the selected drug was automatically linked
to the Anatomical Therapeutic Chemical (ATC) coding
system (http://www.whocc.no). In this study morbiditydata and data on all prescriptions issued by the partici-
pating practices were used. Only individuals of 30 years
and older were included in the statistical analyses, be-
cause individuals below the age of 30 years have a lower
probability of having CVD [14], but also inflammatory
arthritis, osteoarthritis, and/or diabetes mellitus. Prac-
tices that recorded data during less than six months in
2006 were also excluded from the analyses, because the
selection of the patient groups are based on complaints
and diseases presented during GP consultations. When
more than half of the consultations in a year are missing,
the prevalence rates of the studied diseases are
underestimated.
Population selection
Based on the ICPC coded morbidity and prescription
data, it was determined whether the participating
patients had any of the following diagnoses in 2006: 1)
inflammatory arthritis (ICPC code L88; rheumatoid arth-
ritis or ankylosing spondylitis), 2) diabetes mellitus
(ICPC code T90), 3) osteoarthritis of knee and/or hip
(ICPC code L89 and/or L90), 4) CVD (ICPC codes K75
(myocardial infarction), K89 (transient ischemic attack),
and/or K90 (stroke / cerebrovascular accident), 5) hyper-
tension (ICPC code K86 and/or K87) and 6) hyperchol-
esterolemia (ICPC code T93). Individuals were classified
within the above mentioned groups, when the diagnosis
was recorded in 2006 or in previous years (up to 2004).
By using a period of three years, we could determine the
diagnoses more reliable, since not all patients are visiting
their GP every year with complains related to the stud-
ied diseases.
It was not possible to discriminate between rheuma-
toid arthritis and ankylosing spondylitis within the group
of inflammatory arthritis patients and between diabetes
mellitus type 1 and 2. Per patient we also determined
whether they used cardio protective medication (statins
and/or anti-hypertensive agents) in 2006. All other
patients listed in the participating practices without in-
flammatory arthritis, diabetes mellitus and/or osteoarth-
ritis were used as controls.
Statistical analyses
First, CVD prevalence rates were calculated among indi-
viduals with inflammatory arthritis, diabetes mellitus,
osteoarthritis and controls. Differences in age, gender,
the prevalence rates of CVD, hypertension and hyperch-
olesteremia and the use of statins and antihypertensives
between the three patient groups and controls were
tested with Student’s t-test and chi-square tests.
Second, the association between the presence of CVD
and the presence of the three diseases was determined
with multilevel logistic regression analyses with a ran-
dom intercept using the second order PQL method [15]
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clustered in practices). Three models were calculated: 1)
a model with the three studied independent variables
(presence of inflammatory arthritis, diabetes mellitus
and osteoarthritis), 2) model 1 plus age and gender, and
3) model 2 plus CVD risk factors (hypertension and
hypercholesterolemia). Results are presented as odds
ratios with 95%-confidence intervals. Interaction terms
were introduced to test for selective amplification of the
CVD risk by subjects with more than one of the investi-
gated diseases and the possible modifying effect of age.
Multilevel logistic regression analyses were performed
with MLwiN, a statistical program for multilevel ana-
lyses [16]. Student’s t-test and chi-square tests were per-
formed with Stata10.
Results
Population characteristics
Data were used from 175,061 patients in 69 general prac-
tices. Of these patients, 1,518 patients (0.9%) were diag-
nosed with inflammatory arthritis, 11,959 (6.8%) with
diabetes mellitus, and 4,040 (2.3%) with osteoarthritis. The
remaining 158,439 individuals were used as controls. Be-
cause patients can have multiple disorders, the sum of the
number of patients in the four groups exceeds the total of
175,061 patients. The characteristics of the patient groups
and controls are shown in Table 1.
Compared with controls, individuals with inflammatory
arthritis, diabetes mellitus and osteoarthritis were older
and had higher prevalence rates of CVD, hypertension
and hypercholesterolemia. Also, individuals with inflam-
matory arthritis, diabetes mellitus and osteoarthritis were
more often female and used significantly more statins andTable 1 Population characteristics
IA
(n = 1,518)
Mean age, years 60.3**
Female gender,% 64.1**
AMI,% 1.8**
TIA,% 2.0**
CVA,% 3.0**
Total CVD,% 6.5**
Hypertension,% 30.9**
Hypercholesterolemia,% 10.8**
Use of anti-hypertensive agents,% 36.4**
Use of statins,% 15.7**
Inflammatory arthritis,% —
Diabetes mellitus,% 11.5
Osteoarthritis,% 4.4
* p < 0.01; ** p < 0.001 (compared to controls) DM, diabetes mellitus; IA, inflammato
infarction; TIA, transient ischemic attack; CVA, cerebrovascular accident; CVD, cardioanti-hypertensive agents compared with the control group.
The prevalence rate of diabetes mellitus and osteoarthritis
in inflammatory arthritis was 11.5% and 4.4%, respectively.
Association between inflammatory arthritis, diabetes,
osteoarthritis and CVD
Significantly higher CVD rates were found in individuals
with inflammatory arthritis (OR= 2.1), diabetes mellitus
(OR= 3.7), and osteoarthritis (OR= 1.9) compared with
controls (model 1, Table 2). After adjustment for age,
gender and CVD risk factors (hypertension and hyper-
cholesterolemia; model 3), both inflammatory arthritis
and diabetes mellitus were still positively associated with
CVD, but to a lesser extent. We found a larger associ-
ation between inflammatory arthritis and CVD (OR=
1.5) than between diabetes mellitus and CVD (OR= 1.3).
The association between osteoarthritis and CVD
reversed after adjustment for age, gender and CVD risk
factors (OR= 0.8). Interaction terms were added to
model 3 to test for additional effects for subjects with
more than one of the investigated diseases and the
modifying effect of age. However, none of the interaction
terms reached statistical significance (data not shown).
Also, subgroup analyses were performed with myocar-
dial infarction (MI), transient ischemic attack (TIA), and
cerebrovascular accident (CVA) as dependent variables.
After correction for confounders, the association of OA
with these CVD subgroups did not differ from the main
effects, although due to less power these effects did not
reach statistical significance. MI, TIA and CVA were all
positively associated with IA (OR=1.3, OR=1.4 and OR=
1.5, respectively), although only the association between
IA and CVA was statistically significant. For diabetesDM OA Controls
(n = 11,959) (n = 4,040) (n = 158,439)
65.8** 69.8** 51.0
51.9* 68.7** 50.4
2.8** 1.5** 0.7
2.2** 2.0** 0.6
3.7** 2.7** 0.9
8.1** 5.8** 2.0
47.7** 38.5** 13.3
24.0** 13.3** 4.8
60.6** 45.0** 14.6
48.8** 20.0** 6.0
1.5 1.6 —
— 16.5 —
5.6 — —
ry arthritis; OA, knee- and/or hip osteoarthritis; AMI, acute myocardial
vascular disease.
Table 2 Association between CVD and inflammatory
arthritis, diabetes and osteoarthritis
Controls IA DM OA
Model 1 1.0 2.1 (1.7-2.7)* 3.7 (3.5-4.0)* 1.9 (1.6-2.2)*
Model 2 1.0 1.6 (1.3-2.0)* 1.8 (1.6-1.9)* 0.9 (0.8-1.0)
Model 3 1.0 1.5 (1.2-1.9)* 1.3 (1.2-1.4)* 0.8 (0.7-1.0)*
* p <0.001 Results as odds ratios (95%-confidence interval) DM, diabetes
mellitus; IA, inflammatory arthritis; OA, knee and/or hip osteoarthritis.
Model 1: Unadjusted for risk factors.
Model 2: Model 1 adjusted for age and gender.
Model 3: Model 1 adjusted for age, gender, hypertension and
hypercholesterolemia.
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MI and CVA (OR=1.3 and OR=1.4, respectively).
Discussion
There is considerable interest in the association between
inflammatory arthritis and cardiovascular disease, but
evidence from primary care settings emphasizing this
association is sparse. To the best of our knowledge, this
is the first study to report on the CVD prevalence rate
in inflammatory arthritis, diabetes mellitus and osteo-
arthritis patients compared with controls in a nationally
representative primary care population. We report nearly
identical age, sex, hypertension and hypercholesterolemia
adjusted CVD prevalence rates in patients with either in-
flammatory arthritis or diabetes mellitus, supporting our
previous observations that the magnitude of CVD burden
in inflammatory arthritis is comparable with that in dia-
betes mellitus [9,10].
The fact that adjustment for hypertension and hyper-
cholesterolemia attenuated the association between
CVD and diabetes mellitus, but far less so the asso-
ciation between CVD and inflammatory arthritis, is
another important observation. Although it is not pos-
sible to report cause-and-effect relationships with the
cross-sectional design, there are two possible explana-
tions for this observation. First, given the lower preva-
lence rate of hypertension and hypercholesterolemia and
lower use of statins and anti-hypertensive agents in in-
flammatory arthritis patients compared with diabetes
mellitus, one may speculate that classic risk factors are
underreported and hence undertreated in inflammatory
arthritis. CVD risk management is one of the main goals
in the treatment of diabetes mellitus, but, at least until
recently, not in inflammatory arthritis patients, which
supports this hypothesis. Second, factors other than clas-
sic CVD risk factors potentially explain the strong asso-
ciation between inflammatory arthritis and CVD.
Indeed, it is increasingly hypothesized that individuals
with inflammatory arthritis are more affected by CVD
because of a chronic systemic inflammatory process, as
this accelerates the development of all stages of athero-
sclerosis [17]. Inflammatory cells are commonly foundwithin atherosclerotic lesions, particularly in the culprit
lesions, and many inflammatory cells are implicated in
the pathogenesis of atherosclerosis from its earliest
stages [6]. Additionally, inflammation may indirectly in-
crease CVD risk through deteriorating CVD risk factors
[18]. The fact that osteoarthritis (a non-systemic inflam-
matory comparator) did not convey any excess CVD risk
after adjustment for CVD risk factors is another import-
ant observation and may comply with the inflammatory
hypothesis. Surprisingly, after adjustment, osteoarthritis
was negatively associated with CVD. A possible explan-
ation for this finding is selective drop-out (‘healthy sur-
vivors effect’) in the group osteoarthritis patients.
Because of the high mean age of this group (about
70 years old) it is likely that the patients with the highest
risks already died, resulting in an underrepresentation of
the prevalence rate of CVD.
Using data from electronic medical records from general
practices makes it possible to compare the prevalence of
CVD between different patient groups in the same study
population. This has the advantage that all morbidity is
measured in the same manner, minimizing selection bias.
Another strength of this study is the use of a representa-
tive group of patients with a mean average disease severity.
The fact that the observed CVD prevalence rates in in-
flammatory arthritis and diabetes mellitus concur with
other studies lends external validity to our observations
[7]. Also, of important note is the adjustment for import-
ant CVD risk factors (age, gender, hypertension, and
hypercholesterolemia) on the one hand, and controlling
for amplification of CVD risk by individuals with more
than one disease on the other hand. Some other studies
also reported an increased prevalence of CVD in inflam-
matory arthritis from a primary care population, but nei-
ther of these studies controlled for hypertension and/or
hypercholesterolemia [7,8].
Besides the advantage of having access to large represen-
tative patient populations, using data from health regis-
tries also have some disadvantages. First, the large number
of patients makes it impossible to validate diagnoses and
to collect additional data in terms of time and funding. Al-
though diagnoses are not validated by a medical specialist,
the used GP diagnoses are based on the guidelines of the
Dutch College of General Practitioners (NHG). Further-
more, medical specialists send a letter to the GP after the
consultation of a patient with information about diagnosis
and treatment. It is likely that the GP uses this informa-
tion to register the diagnosis inflammatory arthritis in the
EMR of the patient. Therefore, we expect an overesti-
mation of the number of IA patients in our primary care
cohort, which might resulted in an underestimation of our
results. Second, data in health registries are not collected
in a structural way and patients are not measured period-
ically. Data are only available from patients who visit their
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ders, such as smoking and obesity, are not always regis-
tered and these variables cannot be used in the statistical
analyses. Also, not all prescribed drugs in specialised care
are registered in the EMRs of GPs, which makes it not
possible to measure the use of DMARDs reliably. This
hampers us to adjust for these potentially important con-
founders (residual confounding). A limitation of the cross-
sectional design is a lack of information on the sequence
of the disease and CVD events, and hence a causal rela-
tionship between the advent of inflammatory arthritis and
development of CV disease can not be proven.
Conclusions
In conclusion, this is the first study demonstrating an
increased prevalence rate of CVD in inflammatory arth-
ritis to levels broadly similar to diabetes mellitus in a
representative primary care population. The lack of ex-
cess CVD in osteoarthritis further suggests that systemic
inflammatory load appears critical to the CVD burden in
inflammatory arthritis and indirectly underscores the
importance of adequate control of disease activity in in-
flammatory arthritis patients to lower CVD risk.
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